Login to Your Account

Business as Usual as China Bribery Scandal Widens

By Shannon Ellis
Staff Writer

Wednesday, September 4, 2013
SHANGHAI – Four multinational pharmaceutical firms have been hit with allegations of bribery in China since the Glaxosmithkline plc scandal first broke almost two months ago. China’s State Administration for Industry & Commerce (SAIC) has announced a three-month probe that will target pharmaceutical and medical device sales.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription